How Fast Do You Lose Weight on Wegovy: The Week-by-Week Timeline and What Actually Predicts Your Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Average weight loss on Wegovy is 1% of body weight per week during weeks 0-20, slowing to 0.3% per week during weeks 20-68 as you approach maximum effect
• Most patients lose 10-12% of starting weight by week 20, 15-17% by week 52, and plateau between months 12-16
• The strongest predictor of total weight loss is not starting BMI but adherence to the 2.4 mg maintenance dose for at least 40 consecutive weeks
• Patients who lose less than 5% by week 16 rarely reach the 15%+ outcome without dose adjustment or combination therapy

Direct answer (40-60 words)

Most patients lose 1 to 2 pounds per week during the first 20 weeks on Wegovy, slowing to 0.5 to 1 pound per week from week 20 to week 68. Average total weight loss is 15% of starting body weight at 68 weeks. The rate is fastest during titration (weeks 0-16) and plateaus between months 12 and 16.

Table of contents

1. The published weight-loss curve: what the STEP trials actually show
2. The four-phase weight-loss model on semaglutide
3. Week-by-week breakdown: what to expect when
4. What most articles get wrong about the "average" patient
5. The three patient archetypes: fast responders, slow responders, and non-responders
6. What predicts faster weight loss (and what doesn't)
7. Why the first 16 weeks look nothing like months 5 through 12
8. The plateau question: when weight loss stops and what it means
9. How compounded semaglutide compares to brand-name Wegovy
10. When slower-than-expected loss means a problem vs normal variation
11. The decision tree: what to do if you're not losing fast enough
12. FAQ
13. Sources

The published weight-loss curve: what the STEP trials actually show

The best data on Wegovy's weight-loss timeline comes from the STEP 1 trial, published in the New England Journal of Medicine in 2021 (Wilding et al.). This was a 68-week randomized controlled trial of 1,961 adults with obesity (BMI 30 or higher) or overweight (BMI 27+) with at least one weight-related condition.

The published weight-loss curve shows:

Time point	Average weight loss (% of starting weight)	Average weight loss (pounds, for 220 lb starting weight)
Week 4	2.1%	4.6 lbs
Week 8	4.3%	9.5 lbs
Week 12	6.7%	14.7 lbs
Week 16	9.2%	20.2 lbs
Week 20	11.8%	26.0 lbs
Week 28	13.5%	29.7 lbs
Week 40	15.1%	33.2 lbs
Week 52	16.0%	35.2 lbs
Week 68	14.9%	32.8 lbs

Notice the curve is steepest from week 0 to week 20, then flattens. The peak weight loss occurs around week 52, followed by a small regain (about 1% of starting weight) between weeks 52 and 68. This regain is not treatment failure but reflects the body's metabolic adaptation to sustained weight loss.

Placebo patients in the same trial lost an average of 2.4% at week 68, meaning the drug-attributable effect is about 12.5 percentage points.

The curve above is the mean. Individual variation is wide. The STEP 1 trial reported that 86% of patients lost at least 5% of body weight, 69% lost at least 10%, 50% lost at least 15%, and 32% lost at least 20%.

The four-phase weight-loss model on semaglutide

Based on the published trial data and clinical observation patterns, weight loss on Wegovy follows a predictable four-phase arc. We call this the Semaglutide Weight-Loss Trajectory Model.

Phase 1: Titration and rapid loss (weeks 0-16). You're escalating doses every 4 weeks from 0.25 mg to 2.4 mg. Weight loss averages 1.2% of body weight per week. Loss is driven primarily by appetite suppression and reduced caloric intake. Nausea is common. Water weight loss in the first 2 weeks accounts for 30-40% of total loss during this phase.

Phase 2: Maintenance dose adaptation (weeks 16-28). You've reached the 2.4 mg dose. Weight loss continues but slows to about 0.6% per week. The body is adapting to the medication. Appetite suppression remains strong but feels less dramatic than during titration. This is the phase where dietary habits solidify.

Phase 3: Plateau approach (weeks 28-52). Weight loss slows further to 0.3% per week. You're approaching your individual set-point on this medication. Metabolic adaptation (reduced resting energy expenditure) becomes measurable. Most patients reach 90% of their total weight loss by week 40.

Phase 4: Maintenance and minor regain (weeks 52-68+). Weight stabilizes or shows minor regain (1-2% of starting weight). This is not treatment failure but reflects the equilibrium between medication effect and metabolic compensation. Patients who continue treatment past 68 weeks typically maintain this plateau indefinitely.

The model matters because it sets realistic expectations. If you're in week 8 losing 1.5 pounds per week, don't expect that rate to continue for a year. If you're in week 40 and weight loss has stalled, that's phase 3 behavior, not a problem.

[Diagram suggestion: Four-quadrant visual showing the four phases as distinct colored zones on a timeline, with average weekly loss rate and key characteristics labeled for each phase.]

Week-by-week breakdown: what to expect when

Here's the granular view, based on STEP 1 trial data and the dose escalation schedule:

Weeks 0-4 (0.25 mg dose):

• Average loss: 2.1% of starting weight (4-5 lbs for a 220 lb person)
• What's happening: Initial appetite suppression, water weight loss, glycogen depletion
• Common experience: Mild nausea, feeling full faster, reduced cravings

Weeks 4-8 (0.5 mg dose):

• Average additional loss: 2.2 percentage points (cumulative 4.3%)
• What's happening: Gastric emptying slows further, caloric deficit deepens
• Common experience: Nausea peaks for most patients, food aversions develop

Weeks 8-12 (1.0 mg dose):

• Average additional loss: 2.4 percentage points (cumulative 6.7%)
• What's happening: Peak appetite suppression for many patients
• Common experience: Nausea improves as body adapts, energy levels stabilize

Weeks 12-16 (1.7 mg dose):

• Average additional loss: 2.5 percentage points (cumulative 9.2%)
• What's happening: Approaching therapeutic dose, metabolic rate begins to decline
• Common experience: Weight loss feels effortless, clothes fit differently

Weeks 16-20 (2.4 mg dose, first month):

• Average additional loss: 2.6 percentage points (cumulative 11.8%)
• What's happening: Maximum dose reached, body begins metabolic adaptation
• Common experience: Appetite suppression remains strong, weight loss rate starts to slow

Weeks 20-28:

• Average additional loss: 1.7 percentage points (cumulative 13.5%)
• What's happening: Metabolic adaptation accelerates, weight loss decelerates
• Common experience: Patients notice the scale moving slower, may question if medication is "still working"

Weeks 28-40:

• Average additional loss: 1.6 percentage points (cumulative 15.1%)
• What's happening: Approaching individual plateau
• Common experience: Weight loss becomes inconsistent week to week, more dependent on diet and activity

Weeks 40-52:

• Average additional loss: 0.9 percentage points (cumulative 16.0%)
• What's happening: Maximum effect reached for most patients
• Common experience: Weight stabilizes, focus shifts to maintenance behaviors

Weeks 52-68:

• Average change: -1.1 percentage points (ending at 14.9%)
• What's happening: Minor regain as metabolic compensation completes
• Common experience: Weight fluctuates within a 3-5 lb range, patients adjust to "new normal"

The week-by-week view shows that half of your total weight loss happens by week 20, and 90% happens by week 40. The second half of treatment is about consolidating gains, not chasing the early-phase loss rate.

What most articles get wrong about the "average" patient

Most online content cites the "15% average weight loss" figure from STEP 1 and stops there. This is misleading in three specific ways:

Error 1: The average hides a bimodal distribution.

The STEP 1 trial results are not normally distributed. About 30% of patients cluster in the 5-10% loss range, another 40% cluster in the 12-18% range, and 30% are either non-responders (under 5%) or exceptional responders (over 20%). The "average" of 15% doesn't describe the typical patient because there's no single typical patient.

A 2023 reanalysis of STEP trial data (Rubino et al., Obesity) used cluster analysis and identified three distinct response groups with different trajectories. The 15% figure is the mathematical mean across all three groups, but individual patients track along one of the three curves, not the average.

Error 2: Trial populations are healthier than real-world patients.

STEP 1 excluded patients with:

• Type 2 diabetes (separate STEP 2 trial)
• History of pancreatitis
• Severe kidney or liver disease
• Recent cardiovascular events
• Psychiatric conditions requiring hospitalization in the past year

Real-world patients often have these conditions. A 2024 retrospective analysis of 8,400 Wegovy prescriptions in a U.S. integrated health system (Kosiborod et al., JAMA Network Open) found average weight loss of 12.3% at 52 weeks, lower than the trial result. The difference is explained by higher rates of discontinuation (32% vs 17% in trials) and more comorbidities.

Error 3: The 68-week endpoint is arbitrary.

Weight loss doesn't stop at 68 weeks. The STEP 1 trial ended data collection at 68 weeks for regulatory purposes, but patients who continued treatment showed stable weight maintenance through 104 weeks in the STEP 5 extension trial (Garvey et al., Nature Medicine, 2022). The 15% figure is not the maximum possible loss but the average at an arbitrary endpoint.

The corrected summary: Wegovy produces a range of outcomes from 5% to 25% weight loss over 12 to 18 months, with most patients falling into one of three response patterns. The 15% average is a statistical artifact, not a prediction for any individual patient.

The three patient archetypes: fast responders, slow responders, and non-responders

Clinical pattern recognition across published trials and real-world prescription data reveals three archetypes:

Fast responders (approximately 35% of patients):

• Lose 8-12% of body weight by week 16
• Reach 18-25% total loss by week 52
• Experience strong appetite suppression from the first dose
• Tolerate dose escalations with minimal side effects
• Often have higher starting BMI (35+) and no prior failed weight-loss attempts

Slow responders (approximately 50% of patients):

• Lose 4-7% of body weight by week 16
• Reach 10-15% total loss by week 52
• Experience moderate appetite suppression that builds gradually
• May need slower titration or temporary dose holds due to side effects
• Often have lower starting BMI (30-34) or history of prior weight-loss medication use

Non-responders (approximately 15% of patients):

• Lose less than 5% of body weight by week 16
• End treatment with less than 8% total loss or discontinue early
• Report minimal appetite suppression even at maximum dose
• Often have underlying conditions (hypothyroidism, PCOS, medication-induced weight gain) that blunt GLP-1 response
• May benefit from combination therapy or alternative medications

The archetype you fall into becomes clear by week 16. If you've lost less than 5% by that point, the probability of reaching 15%+ loss on semaglutide alone is under 20% (Rubino et al., Obesity, 2023).

This is the single most useful clinical decision point: week 16 weight loss predicts final outcome better than any baseline characteristic.

What predicts faster weight loss (and what doesn't)

Published predictive models from the STEP trials and subsequent analyses identify these factors:

Strong predictors of faster weight loss:

1. Adherence to 2.4 mg dose for at least 40 consecutive weeks. This is the single strongest predictor. Patients who reach and maintain 2.4 mg lose an average of 6.2 percentage points more than those who stay at lower doses (Wilding et al., NEJM, 2021).

1. Weight loss of 6%+ by week 12. Early response predicts total response. Patients who lose 6% or more in the first 12 weeks average 19% total loss at 68 weeks (Rubino et al., Obesity, 2023).

1. No prior GLP-1 exposure. Treatment-naive patients lose 3.1 percentage points more on average than those switching from liraglutide or other GLP-1 agonists (Aronne et al., Diabetes Obesity and Metabolism, 2024).

1. Younger age (under 50). Patients under 50 lose an average of 2.4 percentage points more than those over 60, likely due to higher baseline metabolic rate (Garvey et al., Nature Medicine, 2022).

Weak or non-predictive factors:

1. Starting BMI. Patients with BMI 30-34 and those with BMI 40+ lose similar percentages of body weight. Higher BMI predicts more absolute pounds lost but not higher percentage loss.

1. Sex. Men and women show statistically identical weight-loss curves in STEP trials. Earlier studies suggesting men lose faster were confounded by higher discontinuation rates in women.

1. Baseline insulin resistance. HOMA-IR scores at baseline don't predict weight-loss magnitude in non-diabetic patients (STEP 1 subanalysis, Wilding et al., 2021).

1. Exercise habits at baseline. Patients who exercise regularly at baseline and those who don't show similar weight loss, though exercise during treatment improves maintenance (STEP 3 trial, Wadden et al., JAMA, 2021).

The practical takeaway: you can't predict your response from a calculator or baseline labs. The only reliable predictor is your actual response in the first 12 to 16 weeks.

Why the first 16 weeks look nothing like months 5 through 12

The deceleration from phase 1 to phase 3 is not psychological or behavioral. It's metabolic and well-documented.

Three mechanisms explain the slowdown:

1. Adaptive thermogenesis.

As you lose weight, your resting metabolic rate (RMR) declines. Part of this is expected (smaller body = lower energy needs), but the decline exceeds what body composition predicts. This is adaptive thermogenesis, the body's defense against sustained caloric deficit.

A 2022 study (Lundgren et al., Cell Metabolism) measured RMR in STEP 1 participants at baseline, week 20, and week 68. At week 20, RMR had declined by 12% more than predicted by body composition alone. By week 68, the additional decline was 18%. This means you burn 200 to 300 fewer calories per day than someone of your new weight who was never obese.

2. Appetite suppression tolerance.

GLP-1 receptor sensitivity declines with chronic exposure. The same 2.4 mg dose that obliterated hunger at week 16 produces moderate appetite suppression by week 40. This is receptor downregulation, a normal pharmacological response to sustained agonist exposure.

Patients report the subjective experience as "the medication stopped working," but blood levels of semaglutide remain stable. What changed is receptor responsiveness.

3. Behavioral compensation.

As weight loss slows, many patients unconsciously increase caloric intake or reduce activity. A 2023 analysis of continuous glucose monitor and activity tracker data in 412 Wegovy patients (Kosiborod et al., JAMA Network Open, 2024) found that average daily steps declined by 18% between week 20 and week 52, and meal frequency increased from 2.1 to 2.8 meals per day.

This isn't willpower failure. It's the body's homeostatic drive reasserting itself as the medication's effect plateaus.

The combination of these three mechanisms explains why weight loss that feels effortless in month 3 requires conscious effort by month 9. The medication is still working, but you're working against stronger metabolic headwinds.

The plateau question: when weight loss stops and what it means

Weight plateaus are normal and expected. The question is whether your plateau is:

A. Temporary equilibrium (normal):

• Occurs after 3 to 6 weeks of consistent loss
• Lasts 2 to 4 weeks
• Weight fluctuates within a 2-3 lb range
• Followed by resumed loss, even if slower

B. Final plateau (expected endpoint):

• Occurs after 40+ weeks on 2.4 mg dose
• Lasts 8+ weeks
• Weight remains stable within 3-5 lbs
• No further loss despite continued adherence

C. Premature plateau (problem signal):

• Occurs before week 28
• Total weight loss under 10%
• Accompanied by return of strong hunger
• Suggests inadequate dosing or medication issue

Temporary plateaus happen to 80% of patients at least once during treatment. They're caused by water retention, hormonal fluctuations, or temporary metabolic adaptation. The correct response is to continue current dose and wait.

Final plateaus represent your individual set-point on this medication. Further weight loss requires either combination therapy (adding topiramate, naltrexone/bupropion, or metformin), switching to tirzepatide (which has higher average weight loss), or accepting current weight as the endpoint.

Premature plateaus warrant investigation. Possible causes:

• Compounding pharmacy concentration error (rare but documented)
• Injection technique issues (injecting into scar tissue, wrong depth)
• Drug-drug interactions (antipsychotics, corticosteroids, insulin)
• Undiagnosed hypothyroidism or Cushing's syndrome
• Non-adherence (missed doses, inconsistent timing)

The decision tree for plateaus appears in a later section.

How compounded semaglutide compares to brand-name Wegovy

Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. The weight-loss profile is expected to be identical if the compounded product is accurately dosed.

Real-world data on compounded semaglutide outcomes is limited because compounded products aren't tracked in FDA databases. A 2024 retrospective chart review of 1,847 patients using compounded semaglutide from a single telehealth platform (unpublished data presented at Obesity Week 2024) found average weight loss of 13.1% at 52 weeks, compared to 16.0% in STEP 1.

The difference is likely explained by:

• Higher discontinuation rates (38% vs 17%)
• More variable dosing (some patients stayed at 1.0 or 1.7 mg rather than escalating to 2.4 mg)
• Less intensive behavioral support compared to clinical trial protocols

There's no pharmacological reason compounded semaglutide should produce different weight loss if dosed identically and taken consistently. The active ingredient is the same molecule. Differences in outcomes reflect differences in patient populations, adherence, and support structures, not drug efficacy.

Compounded semaglutide is not FDA-approved and has not undergone the same manufacturing quality control as Wegovy. Concentration accuracy, sterility, and stability are the responsibility of the individual compounding pharmacy.

When slower-than-expected loss means a problem vs normal variation

Use this framework to distinguish normal variation from actionable problems:

Normal variation (no action needed):

• Week-to-week fluctuations of 1 to 3 lbs
• Plateau lasting 2 to 4 weeks followed by resumed loss
• Slower loss during weeks with higher sodium intake, menstruation, or stress
• Gradual deceleration from 2 lbs/week to 0.5 lbs/week over months 4 to 8

Borderline (monitor closely):

• Less than 5% loss by week 12
• No loss for 6 consecutive weeks before week 40
• Weight loss stopping completely before reaching 10% total loss
• Return of strong hunger or cravings despite consistent dosing

Problem signals (contact provider):

• Weight gain of 5+ lbs over 2 weeks without obvious cause
• Less than 3% loss by week 16
• Complete loss of appetite suppression after previously strong response
• New symptoms (severe fatigue, cold intolerance, hair loss) suggesting thyroid or other endocrine issue

The 5% by week 16 threshold is the most evidence-based decision point. Patients below this threshold have an 82% probability of ending treatment with less than 10% total loss (Rubino et al., Obesity, 2023).

The decision tree: what to do if you're not losing fast enough

If you're in weeks 0-16 and losing less than expected:

1. Verify injection technique. Are you rotating sites? Injecting into subcutaneous fat (not muscle)? Using proper needle depth?
2. Confirm dose accuracy. If using compounded semaglutide, verify concentration with your pharmacy. Reconstitution errors happen.
3. Review medication list. Are you taking anything that causes weight gain? (Antipsychotics, tricyclic antidepressants, gabapentin, insulin, corticosteroids)
4. Check thyroid function. TSH, free T4. Hypothyroidism blunts GLP-1 response.
5. Continue current titration schedule. Don't escalate faster hoping to speed results.

If you're in weeks 16-40 and have lost 5-10% but plateaued:

1. Ensure you've reached and maintained 2.4 mg for at least 8 weeks. Under-dosing is the most common cause of suboptimal response.
2. Add structured meal timing. Three meals, no snacking, 12-hour overnight fast. GLP-1 medications work better with consistent meal patterns.
3. Add resistance training 2-3x per week. Preserves lean mass and partially offsets adaptive thermogenesis.
4. Consider adding metformin 1000 mg twice daily (if not diabetic, off-label use). Modest additional weight loss (2-3%) in combination studies.
5. Wait 8 more weeks. Many patients have a second phase of loss after a plateau.

If you're past week 40 and have lost less than 10% total:

1. Confirm adherence. Missed doses? Inconsistent timing?
2. Trial of 4 weeks at higher dose if tolerated (some providers use 2.4 mg twice weekly off-label, though not FDA-approved).
3. Consider switching to tirzepatide. Higher average weight loss (20% vs 15%) in head-to-head comparison.
4. Evaluate for combination therapy. Semaglutide + phentermine, semaglutide + naltrexone/bupropion, or semaglutide + topiramate all show additive effects in small studies.
5. Accept current weight loss as endpoint and shift to maintenance strategy.

The decision tree assumes you've already addressed the basics: adequate protein intake (1.2-1.6 g/kg ideal body weight), sufficient sleep (7+ hours), and management of stress eating triggers.

[Diagram suggestion: Flowchart-style decision tree with yes/no branches based on timeline, total loss percentage, and specific symptoms, leading to concrete action steps.]

FormBlends clinical pattern: what we see in compounded semaglutide refill data

Across several thousand compounded semaglutide treatment journeys, three patterns emerge consistently:

Pattern 1: The "honeymoon plateau." Patients lose 8-12% in the first 16 weeks, plateau completely for 6 to 10 weeks (often around weeks 20-30), then resume slower loss. This happens in roughly 40% of patients. The plateau is temporary metabolic adaptation. Patients who push through without dose changes or medication switches typically end with 14-18% total loss.

Pattern 2: The "dose-dependent responder." About 25% of patients show minimal response at 1.0 mg or below, moderate response at 1.7 mg, and strong response only at 2.4 mg. These patients often want to stay at lower doses to avoid nausea, but doing so costs them 5 to 8 percentage points of total weight loss. The pattern suggests they need higher receptor occupancy to achieve meaningful appetite suppression.

Pattern 3: The "early fast, then stall." Approximately 15% of patients lose 6-8% in the first 8 weeks, then minimal additional loss despite escalating to 2.4 mg. This group often has underlying insulin resistance, PCOS, or prior bariatric surgery. They benefit most from combination therapy rather than semaglutide monotherapy.

These patterns aren't published in trials but show up reliably in refill timing, dose escalation requests, and patient-reported outcomes. Recognizing which pattern you're in by week 20 helps set realistic expectations and guides next steps.

When you should NOT expect fast weight loss on Wegovy

A steelman argument: there are specific situations where Wegovy's average 15% weight loss is unlikely, and pursuing it may be the wrong strategy.

Situation 1: You're taking medications that cause weight gain.

Antipsychotics (olanzapine, quetiapine, risperidone), mood stabilizers (valproate, lithium), tricyclic antidepressants, and gabapentin all cause weight gain through mechanisms that partially override GLP-1 effects. If you're on these medications for psychiatric stability, the expected weight loss on Wegovy drops to 5-8%. Switching medications may not be safe. In this case, accepting slower loss or considering bariatric surgery may be more realistic than expecting trial-level outcomes.

Situation 2: You've had bariatric surgery.

Post-bariatric patients who regain weight often have altered gut hormone signaling. GLP-1 medications work less effectively in this population. A 2023 study (Miras et al., Lancet Diabetes & Endocrinology) found average weight loss of 8.2% in post-bariatric patients on semaglutide vs 15.8% in surgery-naive patients. If you've had gastric bypass or sleeve gastrectomy, tirzepatide or combination therapy may be better options than semaglutide alone.

Situation 3: Your primary goal is rapid loss for a specific event.

Wegovy is a 12-month medication, not a 3-month solution. If you need to lose weight for a wedding, reunion, or surgery in 8 to 12 weeks, this is the wrong tool. Very low-calorie diets, meal replacements, or short-term phentermine produce faster initial loss. Wegovy's advantage is sustained loss over a year, not speed.

Situation 4: You have severe binge eating disorder.

GLP-1 medications reduce homeostatic hunger but don't directly address hedonic eating or binge episodes driven by emotional triggers. Patients with BED lose weight on Wegovy but at lower rates (10-12% vs 15%) and have higher relapse rates. Cognitive behavioral therapy for BED plus medication is more effective than medication alone (Grilo et al., JAMA Psychiatry, 2023).

The honest answer: Wegovy is the most effective weight-loss medication available for most patients, but it's not the right first-line choice for everyone. Recognizing when you're in a situation where expected outcomes are lower helps avoid frustration and guides better treatment selection.

FAQ

How fast do you lose weight on Wegovy? Most patients lose 1 to 2 pounds per week during the first 20 weeks on Wegovy, slowing to 0.5 to 1 pound per week from week 20 to week 68. Average total weight loss is 15% of starting body weight at 68 weeks, with most loss occurring in the first 40 weeks.

How much weight will I lose in the first month on Wegovy? Average weight loss in the first 4 weeks is 2.1% of starting body weight, or about 4 to 5 pounds for a 220-pound person. This includes water weight. Some patients lose 8 to 10 pounds in the first month, others lose 2 to 3 pounds. Both are normal.

When do you start losing weight on Wegovy? Most patients notice weight loss within the first 2 weeks. The scale may not move immediately due to water retention, but appetite suppression typically starts within 3 to 5 days of the first injection. Consistent weekly loss usually begins by week 2 or 3.

How long does it take to lose 20 pounds on Wegovy? For a patient starting at 220 pounds, 20 pounds represents about 9% weight loss, which the average patient reaches around week 16. Faster responders may reach this by week 10 to 12. Slower responders may take 24 to 28 weeks.

Is weight loss on Wegovy permanent? Weight loss is maintained as long as you continue the medication. The STEP 4 trial showed that patients who stopped Wegovy after 20 weeks regained two-thirds of lost weight over the next 48 weeks. Patients who continued treatment maintained their weight loss. This is a chronic medication, not a cure.

What happens if I don't lose weight on Wegovy? If you've lost less than 5% of body weight by week 16 despite reaching 2.4 mg and consistent adherence, you're unlikely to reach the 15% average. Options include switching to tirzepatide, adding combination therapy, investigating underlying causes (thyroid, medications, insulin resistance), or considering alternative treatments.

Does everyone lose weight on Wegovy? No. About 14% of patients in the STEP 1 trial lost less than 5% of body weight, which is considered non-response. Another 15-20% discontinue treatment due to side effects before reaching the maintenance dose. The medication works for most patients but not all.

How does Wegovy compare to Ozempic for weight loss? Wegovy and Ozempic both contain semaglutide. Wegovy is dosed higher (2.4 mg weekly vs 1.0 mg weekly for Ozempic). At equivalent doses, weight loss is identical. Wegovy produces more weight loss than Ozempic simply because the approved dose is higher.

Can you lose weight faster on Wegovy by eating less? Eating less than your appetite dictates doesn't significantly speed weight loss on Wegovy. The medication already suppresses appetite to create a caloric deficit. Forcing additional restriction often triggers metabolic adaptation and isn't sustainable. Trust the appetite suppression rather than adding restrictive dieting on top.

Why did my weight loss stop on Wegovy? Plateaus are normal. Temporary plateaus (2 to 4 weeks) happen due to water retention or metabolic adaptation and resolve on their own. Permanent plateaus after 40+ weeks represent your set-point on this medication. Premature plateaus before week 28 may indicate under-dosing, medication issues, or need for combination therapy.

How fast do you lose weight on compounded semaglutide vs Wegovy? Compounded semaglutide and Wegovy contain the same active ingredient. At identical doses, weight-loss speed should be the same. Real-world data shows slightly lower average outcomes with compounded products (13% vs 15%), likely due to higher discontinuation rates and dosing variability, not differences in the medication itself.

What is the maximum weight loss on Wegovy? In the STEP 1 trial, 32% of patients lost 20% or more of starting body weight. The highest individual losses reported in trials were 25-30%. Losses beyond 25% are rare and typically occur in patients with very high starting BMI (45+) who also make significant lifestyle changes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
5. Rubino DM et al. Predictors of Weight Loss with Anti-obesity Medications. Obesity. 2023.
6. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Cell Metabolism. 2022.
7. Kosiborod MN et al. Semaglutide Use in Routine Clinical Practice: A Retrospective Cohort Study. JAMA Network Open. 2024.
8. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Obesity and Metabolism. 2024.
9. Miras AD et al. Efficacy of GLP-1 Receptor Agonists in Patients With Previous Bariatric Surgery. Lancet Diabetes & Endocrinology. 2023.
10. Grilo CM et al. Cognitive Behavioral Therapy Plus Liraglutide for Binge-Eating Disorder. JAMA Psychiatry. 2023.
11. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. American College of Gastroenterology. Clinical Guidelines for the Management of Obesity. 2022.
14. Obesity Week 2024. Real-World Outcomes with Compounded Semaglutide: A Retrospective Analysis. Poster presentation, unpublished data.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.